-
Ningbo Menovo Pharmaceutical Partners with Nanjing Huawe Medicine for High-End Product Development
•
Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has entered into a strategic partnership with Nanjing Huawe Medicine Technology Group Co., Ltd, a move aimed at leveraging synergies in research and development (R&D) and manufacturing resources. The collaboration seeks to reduce drug development costs and enhance product competitiveness in the high-end…
-
Ningbo Menovo Partners with University of Michigan to Develop GLP-1 Delivery System
•
Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538), a China-based company, has announced a strategic partnership with the University of Michigan in the United States. Financial details of the collaboration remain undisclosed. The partnership will focus on developing an innovative delivery system for glucagon-like peptide-1 (GLP-1) drug targets, with the University…
-
Ningbo Menovo to Sell Zhejiang Liaoyuan Pharma Stake to Jemincare for RMB 512.58M
•
China-based Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has announced plans to transfer all of its ownership in Zhejiang Liaoyuan Pharmaceutical Co., Ltd (23,771,218 shares, or 84.5661% of the target company’s total shares) to Jiangxi Jemincare Group for a consideration of RMB 512.58 million (USD 71.2 million). The deal is…
-
Menovo Pharmaceutical Plans RMB892m Private Placement to Boost API Production
•
China-based Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has announced plans to raise up to RMB892 million (USD131.6 million) through a private placement. The net proceeds will be used for the creation of an active pharmaceutical ingredients (APIs) and intermediates program with an annual output of 3,760 tons, as well…
